Innate Pharma (IPHA) Liabilities and Shareholders Equity (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $73.0 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 38.48% year-over-year to $73.0 million; the trailing twelve-month figure through Dec 2025 stood at $460.0 million (down 33.04% YoY), and the FY2025 full-year result was $73.0 million, down 38.48% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $73.0 million, down from $105.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $320.6 million in Q2 2021 and bottomed at $73.0 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $200.3 million (2022), against an average of $200.3 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity tumbled 99.9%; it then declined 6.66% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $306.0 million in 2021, then tumbled by 30.7% to $212.1 million in 2022, then slipped by 11.12% to $188.5 million in 2023, then plunged by 37.04% to $118.7 million in 2024, then sank by 38.48% to $73.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $73.0 million (Q4 2025), $105.2 million (Q2 2025), and $118.7 million (Q4 2024), per Business Quant data.

Peer Comparison